Using FLT3 Inhibitors to Treat Acute Myeloid Leukemia
A team of researchers at Mass General Cancer Center has reviewed the state of research surrounding FLT3 inhibitors.
Clinical Interests:
Treats:
Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130
Medical Education
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
My research is focused on the development and clinical translation of novel therapies for acute leukemias. I currently lead multiple clinical trials at the Dana Farber Harvard Cancer Center for patients with advanced leukemia and hematologic malignancies. I have a specific interest in studying FLT3 inhibition, aurora kinase inhibition, and antibody-drug conjugates as novel therapies.
Select Publications:
Fathi AT, DiNardo CD, Kline I, Kenvin L, Gupta I, Attar EC, Stein EM, De Botton S. Differentiation syndrome associated with enasidenib (AG-221), a selective inhibitor of mutant isocitrate dehydrogenase 2. JAMA Oncol, 2018;4(8):1106-10.
Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella AP, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood, 2018;132(11):1125-33.
Brunner AM, Neuberg D, Wander SA, Sadrzadeh H, Ballen K, Amrein P, Attar E, Hobbs G, Chen YB, Perry A, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger, DR, Iafrate, A, Graubert TA, Stone R, Fathi AT. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer, 2019;125(4):541-9.
Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein A, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, Van Oostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S. Molecular clearance and response patterns in patients treated with enasidenib, an oral inhibitor of mutant IDH2 proteins. Blood, 2019;133(7):676-87.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
A team of researchers at Mass General Cancer Center has reviewed the state of research surrounding FLT3 inhibitors.
He was excellent and took all the time I needed.
Dr F has been working with me for many years. Be is trusted and respected
The caretakers treat me as family would.
He has always been the best care provider (doctor) that I have ever had. I look forward to all our visits.
When I came in, I saw Dr. Fahti wheel a patient from the patient's room to the waiting room. I was impressed. [redacted] Dr. Fahti, [redacted], and my [redacted] are awesome !!!
Dr. Fathi is an amazing provider. I have a lot of confidence in his knowledge, his ability, his skills, and I appreciate the fact that I can go to Mass General and see him as a provider. That's it.
Dr Fathi was extremely generous in explaining my complex blood related situation so I could understand it.
What I love about Dr. Fathi, besides if you move the I in his name it spells Faith!, Lol. Dr. Fathi, from the first time I saw him as my provider, his personality is amazing, he is always cheerful and smiling, with a very calm speaking voice, he makes you feel you will be okay, you actually forget why you are there in the first place because of ... Read More
Exceptional Caring
I am a Cancer patient and if not for MGB I would most likely not be functioning like I am now after 2 1/2 years. Thank you MGB!